MedTrace Logo

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

NCT04872478 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-08

No results posted yet for this study

Summary

This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.

Conditions

Interventions

DRUG

MRX-2843

MRX-2843 capsules

Sponsors & Collaborators

  • Meryx, Inc.

    lead INDUSTRY

Principal Investigators

  • Melinda Pauley, MD · Emory University, Children's Healthcare of Atlanta

  • William Blum, MD · Emory University

  • Thomas Alexander, MD · UNC Lineberger Comprehensive Cancer Center, Children's

  • Joshua Zeidner, MD · UNC Lineberger Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2026-07-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04872478 on ClinicalTrials.gov